Actelion's Opsumit Shows MERIT In CTEPH

The Switzerland-based biotech Actelion is bullish about new indications and labeling updates for its marketed pulmonary arterial hypertension product macitentan, including in CTEPH, and has also unveiled a promising Phase II candidate for resistant hypertension.

The lung • Source: Shutterstock

Swiss biotech Actelion Pharmaceuticals Ltd. is not only trying to diversify its product portfolio away from pulmonary arterial hypertension (PAH), with Phase III drugs in multiple sclerosis (ponesimod) and Clostridium difficile infection (cadazolid), it is also “committed to remaining a leader in the pulmonary hypertension field,” according to CEO Jean-Paul Clozel.

Extending the reach of marketed drugs with broader indications and line extensions is a well-trodden path for pharmaceutical companies, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category